Literature DB >> 28751080

Non-alcoholic fatty liver disease: A poorly known pandemic.

Salvador Augustin1, Isabel Graupera2, Juan Caballeria3.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) consists of an excessive depositing of fat in the liver, which can end up by causing inflammation, fibrosis and also cirrhosis with the corresponding complications including liver cancer. NAFLD has become the most common liver disease worldwide. The incidence has increased in parallel with the obesity, diabetes and metabolic syndrome epidemic, thus resulting in becoming one of the main indications for liver transplant. The diagnosis has principally been through histology but with the development of non-invasive methods, these have helped in simplifying the management of these patients in clinical practice. The only therapeutic strategies currently available are focused on weight loss (lifestyle changes or bariatric surgery). There is still no approved pharmacological option for the treatment of NAFLD, however there are a number of molecular studies in advanced stages of development.
Copyright © 2017 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Esteatohepatitis; Fatty liver; Hígado graso; Metabolic syndrome; Steatohepatitis; Síndrome metabólico

Mesh:

Year:  2017        PMID: 28751080     DOI: 10.1016/j.medcli.2017.06.026

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  6 in total

1.  Neck Circumference is an Effective Supplement for Nonalcoholic Fatty Liver Disease Screening in a Community-Based Population.

Authors:  Chaohui Jian; Yiting Xu; Xiaojing Ma; Yun Shen; Yufei Wang; Yuqian Bao
Journal:  Int J Endocrinol       Date:  2020-05-16       Impact factor: 3.257

2.  Is Toxoplasma gondii infection correlated with nonalcoholic fatty liver disease?- a population-based study.

Authors:  Jiaofeng Huang; Haoyang Zhang; Shiying Liu; Mingfang Wang; Bo Wan; Bharat Velani; Yueyong Zhu; Su Lin
Journal:  BMC Infect Dis       Date:  2018-12-06       Impact factor: 3.090

3.  Environmental microcystin targets the microbiome and increases the risk of intestinal inflammatory pathology via NOX2 in underlying murine model of Nonalcoholic Fatty Liver Disease.

Authors:  Sutapa Sarkar; Diana Kimono; Muayad Albadrani; Ratanesh K Seth; Philip Busbee; Hasan Alghetaa; Dwayne E Porter; Geoff I Scott; Bryan Brooks; Mitzi Nagarkatti; Prakash Nagarkatti; Saurabh Chatterjee
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

4.  Atherogenic index of plasma is a novel and strong predictor associated with fatty liver: a cross-sectional study in the Chinese Han population.

Authors:  Fangfei Xie; Hong Zhou; Yun Wang
Journal:  Lipids Health Dis       Date:  2019-09-12       Impact factor: 3.876

5.  The Role of Gut Microbiota in Duodenal-Jejunal Bypass Surgery-Induced Improvement of Hepatic Steatosis in HFD-Fed Rats.

Authors:  Yi Gao; Jia Zhang; Xiao Xiao; Yifan Ren; Xiaopeng Yan; Jing Yue; Tieyan Wang; Zheng Wu; Yi Lv; Rongqian Wu
Journal:  Front Cell Infect Microbiol       Date:  2021-04-02       Impact factor: 5.293

6.  Neck circumference as a screening measure for identifying NAFLD among a group of academic employees in Bangkok, Thailand.

Authors:  Sapwarobol Suwimol; Tangkijvanich Pisit; Avihingsanon Anchalee; Kongruttanachok Narisorn; Jantarapakde Jureeporn; Jiamjarasrangsi Wiroj
Journal:  PLoS One       Date:  2022-02-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.